Multiple myeloma is an almost always-fatal blood cancer. But a recent study in the New England Journal of Medicine showed the prescription drug VELCADE increases patients' chances of survival, especially when used earlier in treatment. Dr. Paul Richardson of the Dana-Farber Cancer Institute comments.
This multimedia news story is for free and unrestricted use on your news information site (and for print or broadcast too). Visit http://www.newstream.com to download video, audio, text, graphics and photos.
If you have any questions about the story, or about Newstream.com, please write to us at info@newstream.com.
